BioRestorative Therapies (BRTX) AI Stock Analysis

• Market Cap: $5.82M
• Dividend Yield: N/A
• Average Volume (3M): 229.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 1.70%
• EPS Growth: -111.67%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 21,606,956
• 10 Day Avg. Volume: 28,673
• 30 Day Avg. Volume: 229,747
• PEG Ratio: 0.02
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 27.69
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: 3.64
• Enterprise Value/Gross Profit: 4.57
• Enterprise Value/Ebitda: -0.11
• 1Y Price Target: $1.00
• Price Target Upside: -15.25% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.05
• Revenue Forecast (FY): $2.25M

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-15.25% Downside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is held down primarily by very small and declining revenue, large ongoing losses, and significant cash burn that implies continued external funding needs. Technicals add pressure given the stock’s downtrend versus key moving averages and soft momentum. Offsetting these negatives, recent clinical/regulatory and IP milestones (Fast Track for BRTX-100 and ThermoStem patent progress) support a modestly better earnings-call component, but not enough to overcome weak financial performance.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful advancement of clinical programs, enhancing long-term business prospects.

FDA Fast Track Designation

The FDA Fast Track designation for BRTX-100 accelerates its development and review process, potentially leading to faster market entry and revenue generation.

Strong Financial Position

A strong cash position with no debt provides financial stability, enabling continued investment in R&D and strategic initiatives without immediate financial pressure.

Negative Factors

Ongoing Financial Losses

Persistent financial losses highlight operational challenges and the need for sustainable revenue streams to achieve profitability, impacting long-term viability.

Negative Cash Flow

Negative cash flow indicates reliance on external financing, which may not be sustainable long-term, potentially affecting the company's operational capabilities.

Uncertain Licensing Outcomes

Uncertain outcomes in licensing agreements could delay revenue generation from partnerships, affecting strategic growth and market expansion plans.

BioRestorative Therapies Business Overview & Revenue Model

Company Description

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

How the Company Makes Money

BioRestorative Therapies generates revenue through the development and commercialization of its proprietary cell and tissue-based therapeutic products. The company aims to earn revenue by advancing its clinical programs through various stages of regulatory approval, ultimately leading to product commercialization and sales. Key revenue streams include potential licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies interested in its therapies. Additionally, BRTX may secure funding from grants and research subsidies as it progresses its clinical trials and expands its research initiatives. However, being a biotechnology company in the developmental stage, BioRestorative Therapies may also rely on equity financing and other forms of investment to support its operations until its therapies are fully developed and marketed.

BioRestorative Therapies Financial Statement Overview

Summary

Financials are weak and early-stage: TTM revenue is very small ($0.38M) and down sharply (-36.6%), while losses remain large (EBIT about -$14.5M; net loss about -$12.7M). Cash burn is significant (operating cash flow about -$10.7M; free cash flow about -$10.8M), implying ongoing funding dependence. The main offset is no debt (debt-to-equity 0.0), but equity has declined materially (to about $2.2M), pressuring balance-sheet durability.

Income Statement

TTM (Trailing-Twelve-Months) revenue is small ($0.38M) and declined sharply (-36.6% vs. the prior annual level), indicating an unstable top line. While gross profit is positive and very high as a percent of revenue (about 95% in TTM), operating losses remain extremely large (EBIT about -$14.5M TTM) and the company is deeply unprofitable (net loss about -$12.7M TTM), suggesting the cost structure is still far ahead of revenue capacity.

Balance Sheet

Leverage looks conservative with total debt at $0 in both TTM (Trailing-Twelve-Months) and 2024 and a debt-to-equity ratio of 0.0, reducing refinancing risk. However, equity has fallen materially (from about $21.6M in 2021 to $2.2M in TTM), consistent with ongoing losses and raising balance-sheet durability concerns; returns on equity are also heavily negative in recent periods.

Cash Flow

Cash burn remains significant: operating cash flow is about -$10.7M in TTM (Trailing-Twelve-Months) and free cash flow is about -$10.8M, worse than 2024 levels (about -$8.2M and -$8.3M). Free cash flow has not demonstrated sustained improvement across the annual periods, and cash generation is not yet covering the business’s ongoing operating needs, keeping funding risk elevated.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	383.40K	401.00K	145.80K	119.80K	46.00K	77.00K
Gross Profit	305.23K	372.93K	145.80K	119.80K	46.00K	77.00K
EBITDA	-12.98M	-11.37M	-14.97M	-18.74M	-26.22M	-9.48M
Net Income	-12.67M	-8.98M	-10.42M	-13.22M	-44.30M	-11.27M
Balance Sheet
Total Assets	5.64M	12.28M	12.61M	16.43M	22.45M	4.35M
Cash, Cash Equivalents and Short-Term Investments	4.49M	10.73M	11.07M	14.75M	21.03M	3.06M
Total Debt	0.00	0.00	162.32K	301.64K	670.70K	4.79M
Total Liabilities	3.44M	3.75M	2.61M	6.14M	856.50K	5.68M
Stockholders Equity	2.21M	8.53M	10.00M	10.29M	21.60M	-1.33M
Cash Flow
Free Cash Flow	-10.77M	-8.34M	-6.60M	-6.35M	-3.36M	-1.96M
Operating Cash Flow	-10.72M	-8.23M	-6.43M	-5.91M	-3.33M	-1.96M
Investing Cash Flow	8.03M	514.53K	3.25M	-13.40M	-30.66K	0.00
Financing Cash Flow	1.81M	7.38M	2.35M	0.00	21.32M	5.03M

BioRestorative Therapies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 1.18 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.95, and below the 200-day MA of 1.39, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 19.12 is Positive, neither overbought nor oversold. The STOCH value of 14.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.

BioRestorative Therapies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AEON	54 Neutral	$31.38M	0.23	―	―	―	―
CLRB	53 Neutral	$14.25M	-0.33	-145.42%	―	―	79.31%
MRKR	53 Neutral	$27.18M	-1.26	-110.67%	―	-12.99%	-13.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNSE	51 Neutral	$44.23M	-1.61	-67.47%	―	―	9.63%
COCP	45 Neutral	$13.72M	-1.11	-94.94%	―	―	49.10%
BRTX	44 Neutral	$5.82M	-0.15	-207.73%	―	1.70%	-111.67%

BioRestorative Therapies Corporate Events

BioRestorative Therapies Issues Regulation FD Disclosure

The press release from BioRestorative Therapies does not provide specific information about the company’s industry, primary products, or market focus. The release serves as a formal furnishing of information and clarifies that it is not intended to be a complete or material disclosure for investors. It emphasizes that the information should not be solely relied upon for investment decisions regarding the company’s securities.

The most recent analyst rating on (BRTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on BioRestorative Therapies stock, see the BRTX Stock Forecast page.